Laurence, Rodolphe
Ancel, Julien
Devilliers, Maëva A.
Carre, Sophie
Dury, Sandra
Dormoy, Valérian
Deslée, Gaëtan
Perotin, Jeanne-Marie
Funding for this research was provided by:
Université de Reims Champagne-Ardenne
Reims Métropole
Région Champagne-Ardenne
Fondation du Souffle
Article History
Received: 8 November 2023
Accepted: 9 March 2024
First Online: 15 March 2024
Declarations
:
: The study was approved by the Reims University Hospital. It was conducted under the methodology MR-004 of the French data protection authority (Commission Nationale de l’Informatique et des Libertés, CNIL; 29062021). All patients provided written informed consent.
: Not applicable.
: S. Dury reports lecture honoraria from Boehringer Inhelheim and Sanofi-Aventis; outside the submitted work. V. Dormoy reports lecture honoraria from Chiesi and AstraZeneca; outside the submitted work. G. Deslée reports personal fees from Chiesi, GSK and AstraZeneca; outside the submitted work. J.M. Perotin reports lecture honoraria from AstraZeneca, support for attending meetings from AstraZeneca and Chiesi, and membership of working groups and associations receiving financial support from AstraZeneca, Chiesi, Novartis, and Sanofi; outside the submitted work. There are no further conflicting interests to disclose.